Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Business Wire•01/10/2026•08:30 ET
0
Key Highlights
- ➤Aziz Sawaf appointed Vir Biotechnology (VIR) CFO, effective October 5, 2026
- ➤Sawaf will lead finance, IT and investor relations functions
- ➤Sawaf joins Vir Biotechnology (VIR) from Theravance Biopharma, where he served as CFO since 2023
Expert Statements
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
“I am delighted to welcome Aziz to the executive leadership team. His experience in driving financial performance across the biotech lifecycle, from clinical development through regulatory approval and commercialization, will be a valuable asset for Vir Biotechnology’s next phase of growth.”
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
“Aziz also brings a mindset of disciplined capital allocation, thoughtful investor engagement and tailored strategic partnering.”
Aziz Sawaf, Executive Vice President and Chief Financial Officer of Vir Biotechnology
“I am thrilled to join Vir Biotechnology at this moment in the company’s trajectory as it builds out its differentiated cancer immunotherapy pipeline while continuing to advance a potentially transformative hepatitis delta virus program for patients.”
Aziz Sawaf, Executive Vice President and Chief Financial Officer of Vir Biotechnology
“I look forward to partnering with Marianne, the Board and the entire Vir Biotechnology team to continue to allocate capital with discipline, advance the opportunities with the greatest potential for patients and create durable value for shareholders.”
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr. Sawaf will be responsible for leading the finance, IT and investor relations functions.
Get started
Create a free account to read the full story.